- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Allergan to buy Pa.-based Vicept
Allergan will pay as much as $275 million to acquire Vicept Therapeutics, the Orange County (Calif.) Business Journal reports.
Irvine, Calif. - Allergan, based here, will pay as much as $275 million to acquire Vicept Therapeutics, the Orange County (Calif.) Business Journal reports.
Allergan will pay $75 million for the company, based in Malvern, Pa., and up to $200 million in future milestone payments. Vicept’s V-101, a cream for treating redness associated with rosacea, is in mid-stage clinical trials. Vicept has two other products in the early stages of development.
An Allergan spokesman said the acquisition enhances the company’s dermatology research and development pipeline.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
